Voio

Cover Block

Attribute	Details
Name	Voio
Tagline	Unified AI reading platform for radiology across CT, MRI, X-ray
Headquarters	Berkeley, California, United States
Founded	2025
Stage	Seed
Business Model	B2B
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	Seed (total disclosed ~$8,600,000)

Links

• Website: https://www.voio.ai
• LinkedIn: https://www.linkedin.com/company/voio-ai
• GitHub: https://github.com/voio-ai

Summary and Signal

Voio is a UC Berkeley and UCSF academic spinout building a unified AI platform to interpret radiology scans, entering a crowded market with a team whose prior models have already been validated across hundreds of hospitals [Businesswire, November 2025]. The company's launch wedge is Pillar-0, an open-source model for CT and MRI interpretation that it claims outperforms models from Google, Microsoft, and Alibaba by 10% to 17% in accuracy [Businesswire, November 2025]. This open-source strategy is a deliberate move to foster transparency in a field where AI claims are often difficult for clinicians to verify independently.

The founding team combines deep technical and clinical expertise. CEO Adam Yala is a UC Berkeley computer science professor whose prior work on the Mirai breast cancer risk model has been used in over two million mammograms [Businesswire, November 2025]. He is joined by UCSF radiologist Maggie Chung, MD, and Trevor Darrell, a founding principal investigator of the Berkeley AI Research Lab, providing a foundation in both real-world clinical workflow and advanced computer vision research [STAT, November 2025].

Voio emerged from stealth in November 2025 with an $8.6 million seed round led by Laude Ventures and The House Fund, which also incubated the company through its AI accelerator [Businesswire, November 2025]. The business model is B2B, targeting radiologists and hospital systems with a platform intended to draft reports and integrate imaging history. Over the next 12 to 18 months, the critical watchpoint is the translation of the team's academic validation and open-source model performance into named commercial contracts and regulatory progress.

Data Accuracy: YELLOW -- Core company claims are sourced from its launch press release; team academic backgrounds are corroborated by secondary press coverage.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Seed (total disclosed ~$8,600,000)

Company Overview

Voio is a Berkeley, California based healthtech company that emerged from stealth in November 2025 with an $8.6 million seed round [Businesswire, November 2025]. The company is an academic spinout, founded by UC Berkeley and UCSF faculty to commercialize a line of research in AI for medical imaging that had already seen significant clinical validation outside of a commercial entity.

The founding story centers on the translation of work from Adam Yala's lab at UC Berkeley and collaborators at UCSF, including radiologist Maggie Chung, MD [STAT, November 2025]. Prior to Voio's incorporation, the founders' AI models for mammography and multi-disease detection had been validated in over 92 hospitals across 30 countries and used in more than 2 million mammograms worldwide [Businesswire, November 2025].

Key milestones follow a rapid trajectory from academic project to funded startup. The company was incubated through The House AI Accelerator, receiving its first institutional investment from The House Fund [The House Fund, November 2025]. The public launch in late 2025 coincided with the release of Pillar-0, an open-source foundation model for CT and MRI interpretation, and the announcement of the seed financing led by Laude Ventures and The House Fund [Businesswire, November 2025]. The legal entity, Voio Inc., is registered in Delaware [Crunchbase].

Data Accuracy: YELLOW -- Founding and funding details are confirmed by primary press release and investor statement. The scale of prior academic deployments is reported by the company but not independently verified by third-party sources.

The Product and the Stack

Voio’s commercial proposition is anchored by Pillar-0, an open-source foundation model for medical image interpretation that the company describes as the initial step toward a unified clinical workflow platform. The model is designed to interpret CT and MRI scans across hundreds of pathologies, drafting full radiology reports and connecting images with patient history within a single interface [Businesswire, November 2025]. This approach positions the product as an intelligent assistant intended to help radiologists work faster, with the open-source nature of Pillar-0 serving a specific strategic function: fostering academic validation and transparency in a field where proprietary AI claims are often met with skepticism [STAT, November 2025].

The company’s primary performance claim is that Pillar-0 demonstrates a 10% to 17% accuracy improvement over leading models from Google, Microsoft, and Alibaba [Businesswire, November 2025]. The commercial platform, which builds upon this foundation, is characterized as a unified reading platform spanning CT, MRI, and X-ray. No named commercial customers, FDA clearances, or formal partnership announcements for the Voio platform have been disclosed.

Data Accuracy: YELLOW -- Product claims and performance metrics are sourced from the company's launch announcement; the open-source model is publicly available for verification. Commercial platform details and customer traction are not publicly available.

The Market They Are Entering

The market for AI in medical imaging is defined by the persistent gap between technical promise and clinical workflow integration. Grand View Research estimated the global AI in medical imaging market at $1.4 billion in 2023, projecting a compound annual growth rate of 33.8% through 2030 [Grand View Research, 2023]. This growth is anchored in several demand drivers: a global shortage of radiologists, rising imaging volumes, and the push for value-based care. The STAT report on Voio notes the field is "crowded" but that many solutions remain narrow, single-modality tools that struggle to integrate into radiologists' daily work [STAT, November 2025].

Key adjacent markets include AI-powered clinical decision support software, radiology information systems (RIS), and picture archiving and communication systems (PACS). The regulatory environment, particularly FDA clearance pathways for software as a medical device (SaMD), acts as a significant gating factor for commercial deployment in the United States. While Voio's open-source Pillar-0 model exists outside this framework, any commercial platform offering diagnostic assistance would eventually need to navigate it.

Metric	Value
AI in Medical Imaging Market (Analogous) 2023	1.4 $B
Projected CAGR 2024-2030	33.8 %

Data Accuracy: YELLOW -- Market sizing is an analogous figure from a third-party report; demand drivers and regulatory context are supported by general industry coverage.

The Competitive Field

Voio enters a crowded, high-stakes field where its primary wedge is a claimed performance lead in a foundational open-source model.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Voio	Unified AI reading platform for radiology; open-source Pillar-0 model for CT/MRI.	Seed ($8.6M, 2025)	Claims 10-17% accuracy lead over big-tech models; academic-clinical founder team; open-source validation strategy.	[Businesswire, November 2025]
Google	Enterprise AI/cloud provider with radiology-specific models (e.g., Med-PaLM M).	Public (Alphabet)	Massive compute/data resources; deep integration with Google Cloud ecosystem; broad healthcare AI portfolio.	[Businesswire, November 2025]
Microsoft	Enterprise AI/cloud provider with healthcare cloud and Nuance partnership for clinical documentation.	Public (Microsoft)	Nuance acquisition provides entrenched radiology workflow presence; Azure OpenAI Service integration.	[Businesswire, November 2025]
Alibaba	China-focused cloud & AI giant with medical imaging research.	Public (Alibaba Group)	Dominant in Chinese hospital IT market; large-scale medical imaging datasets from domestic deployments.	[Businesswire, November 2025]

The competitive map in AI radiology is stratified. At the top are the integrated cloud platforms and large incumbent medical imaging vendors. A middle layer consists of venture-backed pure-play AI radiology companies. Voio's initial positioning is distinct: it is not selling a cloud platform or a single-point tool, but a foundational model it claims is superior, released open-source to foster academic validation [Businesswire, November 2025].

Voio's defensible edge today rests on two pillars: academic credibility and strategic openness. The founding team's prior models have been validated in over 92 hospitals across 30 countries and used in more than 2 million mammograms [Businesswire, November 2025]. This edge is durable only if the performance lead holds under independent scrutiny and if the team can translate academic trust into commercial contracts before well-funded rivals close the performance gap.

Data Accuracy: YELLOW -- Competitor positioning and Voio's claims sourced from a single press release; founder academic track record has partial corroboration.

Opportunity

If Voio's performance claims hold and its open-source strategy unlocks trust in a skeptical clinical audience, the company could become the foundational AI reading layer for radiology. The headline opportunity is the establishment of Voio's Pillar models as the de facto standard for AI-assisted diagnosis across hospital radiology departments. Their prior models have been validated in over 92 hospitals across 30 countries and used in more than 2 million mammograms [Businesswire, November 2025].

Scenario	What happens	Catalyst	Why it's plausible
Academic Network Monetization	The 92+ hospitals already using the founders' academic tools convert to paid Voio platform licenses.	A major academic medical center publicly adopts Voio for clinical use.	The team's existing relationships and validation history lower the barrier to a first commercial reference [STAT, November 2025].
Regulatory-Clearance Land Grab	Voio secures FDA 510(k) clearance for a key Pillar model application.	First FDA submission and clearance for a specific pathology.	Founders include a practicing radiologist familiar with the regulatory pathway [The House Fund, November 2025].
Pillar as the Foundational Model	Voio's open-source model becomes the base layer for other health AI startups and research consortia.	A major research initiative formally adopts Pillar-0 as its benchmark model.	The open-source release is explicitly designed to foster this kind of academic validation [Businesswire, November 2025].

Data Accuracy: YELLOW -- The core opportunity thesis relies on company claims of performance superiority and prior academic deployment scale, which are cited in a single press release. The founding team's backgrounds are corroborated by multiple independent sources.

Sources

1. [Businesswire, November 2025] Voio Emerges From Stealth to Build Frontier AI for Healthcare | https://www.businesswire.com/news/home/20251120993306/en/Voio-Emerges-From-Stealth-to-Build-Frontier-AI-for-Healthcare
2. [STAT, November 2025] In crowded AI radiology field, Voio tries to play leapfrog | https://www.statnews.com/2025/11/20/ai-berkeley-voio-diagnose-diseases-from-medical-images/
3. [Crunchbase] Voio - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/voio-558e
4. [The House Fund, November 2025] The House Fund LinkedIn Post on Voio Funding | https://www.linkedin.com/company/the-house-fund/posts/
5. [Grand View Research, 2023] AI In Medical Imaging Market Size Report, 2023-2030 | https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-ai-medical-imaging-market-report